vs
Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and Vericel Corp (VCEL). Click either name above to swap in a different company.
CareTrust REIT, Inc. is the larger business by last-quarter revenue ($134.9M vs $92.9M, roughly 1.5× Vericel Corp). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 25.0%, a 57.5% gap on every dollar of revenue. On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs 23.3%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs 34.6%).
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
CTRE vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $134.9M | $92.9M |
| Net Profit | $111.3M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 82.5% | 25.0% |
| Revenue YoY | 55.1% | 23.3% |
| Net Profit YoY | 113.5% | 17.3% |
| EPS (diluted) | $0.52 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $134.9M | $92.9M | ||
| Q3 25 | $132.4M | $67.5M | ||
| Q2 25 | $112.5M | $63.2M | ||
| Q1 25 | $96.6M | $52.6M | ||
| Q4 24 | $86.9M | $75.4M | ||
| Q3 24 | $77.4M | $57.9M | ||
| Q2 24 | $68.9M | $52.7M | ||
| Q1 24 | $63.1M | $51.3M |
| Q4 25 | $111.3M | $23.2M | ||
| Q3 25 | $74.9M | $5.1M | ||
| Q2 25 | $68.5M | $-553.0K | ||
| Q1 25 | $65.8M | $-11.2M | ||
| Q4 24 | $52.1M | $19.8M | ||
| Q3 24 | $33.4M | $-901.0K | ||
| Q2 24 | $10.8M | $-4.7M | ||
| Q1 24 | $28.7M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | — | 24.1% | ||
| Q3 25 | 58.1% | 5.1% | ||
| Q2 25 | 61.3% | -3.2% | ||
| Q1 25 | — | -24.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | 43.0% | -4.3% | ||
| Q2 24 | 15.1% | -11.5% | ||
| Q1 24 | — | -10.7% |
| Q4 25 | 82.5% | 25.0% | ||
| Q3 25 | 56.6% | 7.5% | ||
| Q2 25 | 60.9% | -0.9% | ||
| Q1 25 | 68.1% | -21.4% | ||
| Q4 24 | 60.0% | 26.3% | ||
| Q3 24 | 43.2% | -1.6% | ||
| Q2 24 | 15.6% | -8.9% | ||
| Q1 24 | 45.6% | -7.5% |
| Q4 25 | $0.52 | $0.46 | ||
| Q3 25 | $0.35 | $0.10 | ||
| Q2 25 | $0.35 | $-0.01 | ||
| Q1 25 | $0.35 | $-0.23 | ||
| Q4 24 | $0.30 | $0.40 | ||
| Q3 24 | $0.21 | $-0.02 | ||
| Q2 24 | $0.07 | $-0.10 | ||
| Q1 24 | $0.22 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.0M | $137.5M |
| Total DebtLower is stronger | $894.2M | — |
| Stockholders' EquityBook value | $4.0B | $354.6M |
| Total Assets | $5.1B | $488.0M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.0M | $137.5M | ||
| Q3 25 | $712.5M | $135.4M | ||
| Q2 25 | $306.1M | $116.9M | ||
| Q1 25 | $26.5M | $112.9M | ||
| Q4 24 | $213.8M | $116.2M | ||
| Q3 24 | $377.1M | $101.7M | ||
| Q2 24 | $495.1M | $102.5M | ||
| Q1 24 | $451.2M | $110.6M |
| Q4 25 | $894.2M | — | ||
| Q3 25 | $893.8M | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $822.1M | — | ||
| Q4 24 | $396.9M | — | ||
| Q3 24 | $396.7M | — | ||
| Q2 24 | $671.1M | — | ||
| Q1 24 | $595.9M | — |
| Q4 25 | $4.0B | $354.6M | ||
| Q3 25 | $4.0B | $321.9M | ||
| Q2 25 | $3.3B | $306.8M | ||
| Q1 25 | $2.9B | $295.5M | ||
| Q4 24 | $2.9B | $292.0M | ||
| Q3 24 | $2.4B | $257.5M | ||
| Q2 24 | $1.9B | $243.0M | ||
| Q1 24 | $1.7B | $233.9M |
| Q4 25 | $5.1B | $488.0M | ||
| Q3 25 | $5.1B | $453.3M | ||
| Q2 25 | $4.7B | $435.6M | ||
| Q1 25 | $3.9B | $424.6M | ||
| Q4 24 | $3.4B | $432.7M | ||
| Q3 24 | $2.9B | $390.4M | ||
| Q2 24 | $2.7B | $376.8M | ||
| Q1 24 | $2.3B | $356.7M |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $394.0M | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | 3.54× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $394.0M | $15.0M | ||
| Q3 25 | $100.9M | $22.1M | ||
| Q2 25 | $100.8M | $8.2M | ||
| Q1 25 | $71.4M | $6.6M | ||
| Q4 24 | $244.3M | $22.2M | ||
| Q3 24 | $67.2M | $10.2M | ||
| Q2 24 | $53.0M | $18.5M | ||
| Q1 24 | $48.8M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 27.3% |
| Q4 25 | 3.54× | 0.65× | ||
| Q3 25 | 1.35× | 4.35× | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 4.68× | 1.12× | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRE
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
